Abbasinejad employs specific strategies to minimize your discomfort: Slow Titration: We start you on a low dose and increase it very slowly
iScience 16 , 326339 (2019)
All linked inline where referenced
18.2% average weight loss at week 68 was observed in patients in the STEP 4 trial, along with reduced blood glucose levels, improved lipid profile and significant improvements in overall quality of life and health status scores
The clinical determination of which is more appropriate for you belongs to your assigned provider, not the marketing copy of either medication
Additionally, in another Phase II study targeting patients with T2DM, orforglipron also showed significant effects in reducing A1C and weight, achieving the studys primary and secondary endpoints